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Between 2004 and 2010, 189 adult patients were enrolled on the National Cancer Institute’s cross-sectional
chronic graft-versus-host disease (cGVHD) natural history study. Patients were evaluated by multiple disease
scales and outcome measures, including the 2005 National Institutes of Health (NIH) Consensus Project
cGVHD severity scores. The purpose of this study was to assess the validity of the NIH scoring variables as
determinants of disease severity in severely affected patients in efforts to standardize clinician evaluation and
staging of cGVHD. Out of 189 patients enrolled, 125 met the criteria for severe cGVHD on the NIH global score,
62 of whom had moderate disease, with a median of 4 (range, 1-8) involved organs. Clinician-assigned
average NIH organ score and the corresponding organ scores assigned by subspecialists were highly corre-
lated (r ¼ 0.64). NIH global severity scores showed signiﬁcant associations with nearly all functional and
quality of life outcome measures, including the Lee Symptom Scale, Short Form-36 Physical Component Scale,
2-minute walk, grip strength, range of motion, and Human Activity Proﬁle. Joint/fascia, skin, and lung
involvement affected function and quality of life most signiﬁcantly and showed the greatest correlation with
outcome measures. The ﬁnal Cox model with factors jointly predictive for survival included the time from
cGVHD diagnosis (>49 versus 49 months, hazard ratio [HR] ¼ 0.23; P ¼ .0011), absolute eosinophil count at
the time of NIH evaluation (0-0.5 versus >0.5 cells/mL, HR ¼ 3.95; P ¼ .0006), and NIH lung score (3 versus
0-2, HR ¼ 11.02; P < .0001). These results demonstrate that NIH organs and global severity scores are reliable
measures of cGVHD disease burden. The strong association with subspecialist evaluation suggests that NIH
organ and global severity scores are appropriate for clinical and research assessments, and may serve as
a surrogate for more complex subspecialist examinations. In this population of severely affected patients, NIH
lung score is the strongest predictor of poor overall survival, both alone and after adjustment for other
important factors.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.edgments on page 638.
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13.01.013INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is curative for many diseases. However, roughly 50% of
allo-HSCT recipients develop chronic graft-versus-host-
disease (cGVHD), a serious and potentially life-threateningSociety for Blood and Marrow Transplantation.
Table 1
Patient Characteristics
Characteristic n (%)
Sex
Male 99 (52)
Female 90 (48)
Disease
ALL/AML/MDS 78 (41)
CML 30 (16)
CLL 14 (7)
Lymphoma 42 (22)
Multiple myeloma 15 (8)
Aplastic anemia/PNH 6 (3)
Other 4 (2)
Stem cell source
Bone marrow 35 (18.5)
Peripheral blood 153 (81)
Cord blood 1 (0.5)
Donor-recipient relationship
Related 130 (69)
Unrelated 59 (31)
Age
<40 years 58 (31)
40 x <60 years 110 (58)
60 years 21 (11)
Recipient CMV status at transplantation
Positive 59 (31)
Negative 50 (26)
Unknown 80 (43)
Myeloablative
Yes 102 (54)
No 86 (65)
Unknown 1 (0.5)
HLA match
Yes 156 (83)
No 29 (15)
Unknown 4 (2)
Sex mismatch
Male-male 47 (25)
Male-female 44 (23)
Female-female 41 (22)
Female-male 41 (22)
Unknown 16 (8)
Time from transplantation
K. Baird et al. / Biol Blood Marrow Transplant 19 (2013) 632e639 633long-term complication [1]. cGVHD is a multisystem alloim-
mune disorder characterized by immune dysregulation,
immunodeﬁciency, impaired organ function, and decreased
survival. Five-year survival rates for patients who develop
cGVHD range from 40% to 70%, and complications from
cGVHD are the primary cause of nonrelapse mortality in
patients more than 2 years after allo-HSCT [1-3]. Up to one-
half of patients fail front-line therapy and require second-
line therapies, which often result in partial or short-lived
responses, drug toxicity, and decreased quality of life (QoL)
and functional ability [4].
Important barriers to clinical research in cGVHD include
the absence of standardized criteria for diagnosis, staging,
and response criteria to systematically study this rare disease
[5]. Over the past several years, the transplantation
community has come together to systematically study
cGVHD under the guidelines provided by the National
Institutes of Health (NIH)-sponsored cGVHD Consensus
Project. The cGVHD Consensus Project is an international
collaborative effort that has uniﬁed the transplantation
community’s approach to the disease through the compila-
tion of focused working groups [5-10].
The purpose of the present study was to validate the NIH
organ and global severity scores as determinants of cGVHD
disease severity in a prospectively established cohort of
patients. We used the cGVHD organ score proposed by Fili-
povich et al. [5] to standardize the criteria for staging after
the diagnosis of cGVHD is made, to score cGVHD organ
involvement, and assess overall severity and level of func-
tional impairment. This tool was applied to a population of
patients with predominately severe cGVHD, which was
primarily referral-based and enriched for organ manifesta-
tions most likely to contribute the greatest disease burden.
Here we present results for 189 patients evaluated exten-
sively on the National Institutes of Health (NIH) cGVHD
Natural History study, comparing detailed expert evaluations
using the NIH Consensus Project criteria tools.<360 (<1 year) 30 (16)
360< x <720 (1-2 years) 23 (12)
720< x <1080 (2-3 years) 41 (22)
1080< x <1800 (3-5 years) 44 (23)
>1800 (>5 years) 51 (27)
Classiﬁcation
Classic cGVHD 166 (88)
Overlap cGVHD 23 (12)
cGVHD onset*
Progressive 80 (42)
Quiescent 41 (22)
De novo 67 (35.5)
Unknown 1 (0.5)
Number of previous treatment regimens
<2 19 (10)
2-3 72 (38)
4-5 61 (32)
>5 35 (19)
Unknown 2 (1)
Intensity of immunosuppressiony
None/mild 49 (26)
Moderate 71 (37)
High 69 (37)
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; CLL, chronic lymphocytic leukemia; CMV, cytomegalovirus; MDS,
myelodysplastic syndrome; PNH, paroxysmal nocturnal hemoglobinuria.
* Deﬁnitions of cGVHD onset are as follows: progressive (acute GVHD
progressed directly to cGVHD); interrupted (acute GVHD resolved, then
cGVHD developed); de novo (acute GVHD never developed). Overlap
cGVHD is deﬁned as features of both cGVHD and acute GVHD, such as
erythematous skin and diarrhea [5].
y None/mild, single-agent prednisone 0.5 mg/kg per day; moderate,
single-agent prednisone 0.5 mg/kg/day and/or any single agent/modality;
high, 2 or more agents/modalities  prednisone 0.5 mg/kg/day [16].METHODS
Study Design
This is a cross-sectional natural history study of patients with cGVHD
evaluatedat theNIHbetweenOctober2004 andAugust 2010. TheNIHcGVHD
program has established a multidisciplinary clinic and research network to
study the pathogenesis and natural history of cGVHD. The foundation of this
program is based on the natural history protocol Prospective Assessment of
Clinical and Biological Factors Determining Outcomes in Patients with
Chronic Graft-Versus-Host Disease (NCT00092235), a National Cancer Insti-
tute Institutional Review Boardeapproved, nontherapeutic study empha-
sizing cross-sectional data and specimen collection.
Between October 2004 and August 2010, a total of 217 consecutive
patients were enrolled. Nine patients were ineligible owing to an inability to
conﬁrm the diagnosis of cGVHD. Two patients were eliminated who were
diagnosed with late-acute GVHD with no evidence of cGVHD. Finally, 17
patients were children or adolescents and were not used for this investi-
gation. Consequently, 189 adult patients met the criteria speciﬁed in the NIH
cGVHD Consensus Project criteria [5] deﬁnition and were included in this
analysis (Table 1).
The natural history protocol involves comprehensive systematic multi-
specialty patient evaluation, comprehensive history and physical examina-
tion, functional measurements, and QoL assessments. Skin, oral, and salivary
gland biopsy analyses, imaging studies, and laboratory tests were performed
as well. During the 1-week evaluation, NIH organ and global severity scores
were assigned by a mid-level provider with attending physician review [5].
Of note, when assigning the lung NIH organ score, the lung function score
(LFS) was used when pulmonary function test (PFT) data were available,
with symptoms used only in the absence of PFT data. The LFS was computed
based on the extent of forced expiratory volume in 1 second (FEV1) and
diffusion capacity of the lung for carbon monoxide (DLCO) compromise (see
Supplemental Materials) [5]. When a discrepancy existed between pulmo-
nary symptoms and PFT scores, the higher value was used for ﬁnal scoring.
Table 2
NIH cGVHD Global and Organ Severity Scores
Score n (%)
NIH global severity score
1 ¼ mild 2 (1)
2 ¼ moderate 62 (33)
3 ¼ severe 125 (66)
NIH organ severity scores
Skin
0 ¼ none 42 (22)
1 ¼ mild 30 (16)
K. Baird et al. / Biol Blood Marrow Transplant 19 (2013) 632e639634All but 3 of our patients had PFT data available for scoring. Patients also
underwent extensive subspecialist evaluation (SSE) with in-depth subspe-
cialty grading of the key organs, such as the Schubert Scale for oral
involvement [11], Schirmer’s tear test and eye examination, and the NIH skin
response scale [8]. Key organ assessments encompassed 9 domains: dental,
dermatology, ophthalmology, occupational therapy and physiatry, pulmo-
nary, gynecology, gastroenterology, and 2 laboratory assessments: platelets
and liver function tests (including bilirubin, alkaline phosphatase, aspartate
aminotransferase, and alanine aminotransferase). These scores were
subsequently converted to a 4-point scale similar to the NIH organ severity
score, with 0 ¼ no involvement, 1 ¼ mild, 2 ¼ moderate, and 3 ¼ severe
involvement (see Supplemental Materials for the SSE and 4-point conver-
sion scale).
All patients were evaluated by subspecialists in dentistry, dermatology,
ophthalmology, occupational therapy and physiatry, and gynecology
(females only). Pulmonology and gastroenterology evaluations were per-
formed only in selected patients, and scoring for these organ systems relied
on PFT data and patient-reported symptoms. All evaluations were per-
formed by a limited number of subspecialists (eg, 1 of 2 dermatologists, 1 of
3 ophthalmologists, 1 of 3 physiatrists), all of whom were experts in the
evaluation of GVHDwith a minimum of 5 years experience and publications
in the ﬁeld of cGVHD, and several of whom were involved in the develop-
ment of the NIH Consensus Project criteria for cGVHD.
The average NIH scoreswere calculated by dividing the total score by the
number of total domains (organs) measured (8 for females and 7 for males).
The mean score for the study population was determined by averaging the
means of all individual average NIH scores. Similarly, average SSE scores
were calculated for each patient by dividing the total score by the total
domains measured (8 for males and 9 for females). Note that the SSE global
scale includes a measure of platelet count, which is not currently used in the
NIH organ scores.
Patients also underwent 9 continuous variable outcome measures: Lee
Symptom Scale [12], Short Form-36 (Physical and Mental Component
Scales) [13], Functional Assessment of Cancer TherapyeBone Marrow
Transplant [14], Human Activity Proﬁle Maximal Activity Score/Adjusted
Activity Score [15], 2-minute walk test, grip strength, and joint range of
motion. NIH scores were compared with categorical outcomes: intensity of
immunosuppression scale [16], therapeutic intent of GVHD at enrollment as
deﬁned according to Mitchell et al. [17], and clinician 7-point global
assessment of change [8]. See the Supplemental Materials for complete
deﬁnitions of terms.2 ¼ moderate 46 (24)
3 ¼ severe 71 (38)
Mouth
0 ¼ none 59 (31)
1 ¼ mild 104 (55)
2 ¼ moderate 23 (12)
3 ¼ severe 3 (1.5)
Eyes
0 ¼ none 33 (17)
1 ¼ mild 66 (35)
2 ¼ moderate 69 (36)
3 ¼ severe 21 (11)
Gastrointestinal tract
0 ¼ none 107 (57)
1 ¼ mild 62 (33)
2 ¼ moderate 14 (7)
3 ¼ severe 6 (3)
Liver
0 ¼ none 91 (48)
1 ¼ mild 64 (34)
2 ¼ moderate 34 (18)
3 ¼ severe 0
Lungs
0 ¼ none 45 (24)
1 ¼ mild 79 (42)Statistical Analysis
Univariate associations between a set of predictors and a set of
outcomes were initially determined. Statistical methods used in these
univariate analyses included the following: Wilcoxon rank-sum test, Meh-
ta’s modiﬁcation to Fisher’s exact test [18], Jonckheere-Terpstra trend test
[19], Cochran-Armitage trend test [20], Kruskal-Wallis test, and Spearman
rank correlation. Spearman correlations are interpreted as follows: jrj >
0.70 ¼ strong correlation; 0.5 < jrj < 0.7 ¼ moderately strong correlation;
0.3 < jrj < 0.5 ¼ weak to moderately strong correlation; jrj < 0.3 ¼ weak
correlation.
Survival analyses were done beginning at the date of entry onto the
natural history protocol until death or last follow-up. Kaplan-Meier analyses
and log-rank tests were used to determine the association between poten-
tial predictors and survival after entering on the trial. When data were
initially evaluated in 3 or more groups (such as with quartiles for a contin-
uous parameter), the unadjusted P value presented represents the result for
a comparison based on combining data into 2 groups with differing prog-
nosis. The adjusted P value is the unadjusted P value multiplied by the
number of implicit comparisons, which were performed to end up with the
most signiﬁcant result shown. Following these univariate analyses, Cox
proportional hazards models were constructed to determine the joint
association between the factors of potential interest and survival. Except as
noted above, all P values are 2-tailed and presented without formal
adjustment for multiple comparisons.2 ¼ moderate 42 (22)
3 ¼ severe 23 (12)
Joints and fascia
0 ¼ none 75 (40)
1 ¼ mild 40 (21)
2 ¼ moderate 55 (29)
3 ¼ severe 19 (10)
Genital (female only; n ¼ 90)
0 ¼ none 46 (51)
1 ¼ mild 13 (14)
2 ¼ moderate 13 (14)
3 ¼ severe 18 (9)RESULTS
Patient Population
The patient population was well balanced for sex (99
males, 90 females), with an average on-study age of 48 years
(range, 18-70 years) and a median time from transplant of 37
months (range, 4-258 months) and median time from
cGVHD diagnosis of 23 months (range, 0-222 months)
(Table 1). The majority of patients (89%) were transplanted
for hematologic malignancies, and approximately one-half ofthe population was cytomegalovirus-positive at trans-
plantation (if status was known). More than two-thirds (69%)
had a related donor transplant and 83% were complete HLA
matches. Sex mismatch was equally distributed between M/
M, M/F, F/F, and F/M, and the majority (81%) received
peripheral blood stem cells (PBSCs) as their graft source.
More than half (54%) received a myeloablative preparative
regimen. Three-quarters pf the patients (n ¼ 140) were on
moderate or high immunosuppression, and the remainder
were on none or mild immunosuppression at the time of
evaluation.
cGVHD Characteristics
Overall, 125 of 189 patients (66%) were categorized as
severe by the NIH global score (Table 2); the median number
of involved organs was 4 (range, 1-7) in the moderate cGVHD
group and 5 (range, 1-8) in the severe cGVHD group. The
patients had a median number of 4 previous treatment
regimens (range, 0-9); 88% were characterized with classic
cGVHD and 12% ere classiﬁed with overlap GVHD. The onset
of cGVHD was progressive in 42%, de novo in 35%, and
quiescent in 22% (Table 1). The median Lee Symptom Scale
score was 34 (range, 1-83). The most commonly involved
Figure 1. Patients with cGVHD involvement per organ. A score of 1 on the NIH scale is reﬂected by the blue bar, and a score of 3 (severe) is represented by the red
bar. Although eye, oral, and skin are the most commonly involved organs, severity in the overall cohort was driven by severe skin disease and a high percentage of
lung involvement.
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(Figure 1 and Table 2). Lung scores were based on the LFS, as
calculated from PFT results, in all but 3 patients, who unable
to complete PFTs and thus had a lung score based on
symptoms only. Organ severity was driven primarily by skin
disease, followed by lung, joint/fascia, eye, and genital
involvement (Figure 1). Interestingly, patients with available
self-reported data (n ¼ 133) generally reported lower global
severity compared with that assigned by clinicians (Table 3).
Note that the self-report questionnaire was added after the
protocol opened and thus was not available for the initial 56
patients enrolled on the study.
Skin, eye, and oral GVHD scores assigned by clinicians and
by SSEs (dermatologist, ophthalmologist, and dentist) were
comparable. NIH skin, eye, and oral scores were associated
with standard quantitativemeasures, including percent body
surface area, oral Schubert Scale score, and Schirmer’s test,
each with 2-sided P values of <.0001 (data not shown). The
average clinician-assigned NIH score was 1.09 (range, 0.14-
2.14), which was comparable to the average SSE-assigned
score of 0.98 (range, 0.13-1.88). Direct comparison of the
average SSE score to the average NIH score showed
a moderately strong correlation (Spearman correlation
coefﬁcient ¼ 0.64) (Figure 2).
cGVHD Score and Outcomes
NIH global severity scores showed signiﬁcant associations
(P  .001 to  .05) with almost all functional and QoL
outcome measures: Lee Symptom Scale; Short Form-36
Physical Component Scale, 2-minute walk, grip strength,
range of motion, Human Activity Proﬁle Maximal Activity
Score/Adjusted Activity Score, and Functional Assessment of
Cancer TherapyeBone Marrow Transplant; the sole excep-
tionwas the SF-36 Mental Component Scale (Figure 3). Joint/
fascia, skin, and lung disease had the most signiﬁcant affect
on function and QoL, demonstrating the highest number of
signiﬁcant associations with almost all outcome measures
(Figure 3).Table 3
NIH cGVHD Global Severity Scores
Provider Patient
Mild, n 4 39
Moderate, n 64 65
Severe, n 121 29
Unavailable, n 56The impact of skin on functional and QoL outcome
measures is driven primarily by sclerotic involvement.
Joints/fascia and skin scores, but not lung scores, were
signiﬁcantly associated with intensity of immunosuppres-
sion (P < .0001 for both), therapeutic intent at the time of
evaluation (P < .0001 for both), and clinician 7-point global
assessment of change (P < .0001 for both). Average NIH
scores were also highly associated with SSE scores, intensity
of immunosuppression, therapeutic intent, and global
assessment of change. The Lee Symptom Scale was affected
by organ involvement in most organs, but was most strongly
correlated with gastrointestinal score and an NIH global
severity score of severe.
cGVHD Score and Survival
The median follow-up of surviving patients was 57.4
months, with an overall survival of approximately 76% at 36
months (Figure 4A). In univariate analyses, a Karnofsky
Performance Score (KPS) of80 versus<80 was signiﬁcantly
associated with greater probability of survival, (P ¼ .0001)
(Figure 4B), as was an eosinophil count of 0-0.5 cells/uL
versus>0.5 cells/uL (P¼ .0022) (Figure 4C). Overwhelmingly,
an NIH lung severity score of 3 versus <3 was the most
strongly negatively associated with survival (3-yearFigure 2. Comparison of average NIH organ score to the expert SSE average
score, shows a moderately strong correlation (Spearman r ¼ 0.64 [strong, r >
0.70]). The scores show impressive correlation considering the SSE score is
a strictly objective assessment versus the NIH score, which integrates patient
reported symptoms and/or need for treatment.
Figure 3. Comparison of the NIH Organ Score to 10 outcome variables that are related to disease severity in patients with chronic disease. Scores with highly
signiﬁcant association with the outcome measure are indicated in the solid blocks (P < .001) and those with a trend toward signiﬁcance are represented by striped
blocks (P < .05).
K. Baird et al. / Biol Blood Marrow Transplant 19 (2013) 632e639636estimated survival of 35% versus 82%; P < .0001) (Figure 4D).
In addition, a FEV1 score >57% versus 57%, time from
cGVHD to study enrollment>49months versus49months,
and NIH skin score 0-2 versus 3, were associated with
improved survival (data not shown). An average NIH score
<1.4 versus 1.4 trended toward signiﬁcance, with unad-
justed P ¼ .07 and adjusted P ¼ .21 (data not shown).Figure 4. Kaplan-Meier survival curves for the entire cohort (A) from the time enrolle
count (C), but the best predictor of outcome was the NIH lung severity score (D), in whiIn Cox proportional hazards analysis, adjusting for
demographic and clinical parameters including time from
transplantation, time from cGVHD diagnosis, degree of
immunosuppression, and known predictors of cGVHD
mortality (ie, hyperbilirubinemia, thrombocytopenia, eosin-
ophilia, and low KPS), the ﬁnal model contained time from
diagnosis of cGVHD49 months versus>49 months (hazardd on study. KPS was associated with survival (B) in this cohort as was eosinophil
ch a severe score (¼3) was the most likely indicator of poor survival (P< .0001).
K. Baird et al. / Biol Blood Marrow Transplant 19 (2013) 632e639 637ratio [HR], 0.23; 95% conﬁdence interval [CI], 0.09-0.56;
P ¼ .0011), absolute eosinophil count of 0-0.5 cells/uL
versus >0.5 cells/uL (HR, 3.95; 95% CI, 1.80-8.66; P ¼ .0006),
and NIH lung score of 3 versus 0-2 (HR, 11.02; 95% CI, 5.67-
21.41; P < .0001).
DISCUSSION
This study adds to the growing body of literature sup-
porting the NIH cGVHD severity score as a valid measure of
disease severity in patients with cGVHD and represents an
analysis of NIH organ scores and functional outcomes in
patients with moderately severe cGVHD versus those with
severe cGVHD. The availability of a valid, reproducible tool to
assess patients with cGVHD provides a universal scale for
measuring cGVHD in clinical trials and gives transplantation
physicians a common language. In contrast to reported
studies that included enrolled patients at transplant centers
[21-23], the present study focused on a referral population of
patients enriched for severe and often disabling manifesta-
tions of cGVHD likely to contribute most signiﬁcantly to
patient morbidity. This cross-sectional, prospective study
evaluated a large set of clinician- and patient-reported
outcome measures, including organ-speciﬁc SSEs, to assess
the validity of the proposed NIH Consensus Criteria scores.
Some degree of variability is expected between clinician
and subspecialist scores, considering that the NIH organ
score integrates subjective, patient-reported symptoms and
functional impairment, whereas the expert evaluator scores
are based on objective examination only. Nevertheless,
a high degree of association between clinician and subspe-
cialist scores was found, providing important evidence sup-
porting use of the NIH scores as simple measures to
adequately assess organ involvement. Recent studies also
had validated use of the NIH scores as correlates of QoL [23]
or over time as therapy response criteria [24]. Jacobsohn
et al. [24] reported similar concordance between NIH skin
score and more in-depth skin evaluations; in addition,
changes in NIH skin score were closely correlated with the
Lee Symptom Scale and ultimately with overall survival.
We found a strong correlation between NIH global score
and all outcomes (except the Short Form-36 Mental Com-
ponenet Score), which validates this classiﬁcation as
a measure of cGVHD global severity. In our study population,
severe NIH stage was driven signiﬁcantly by the presence of
sclerotic skin, joints/fascia, and/or lung involvement, and
involvement of these organs also had the greatest effect on
function and QoL, as assessed by patient self-reports as well
as objective measures, such as grip strength and 2-minute
walk time. This is similar to results of the Chronic GVHD
Consortium study reported by Arai et al. [21], in which skin,
lung, and eye ﬁndings were the most signiﬁcant indicators of
severity. However, although the eyes were the most
frequently affected organ in our cohort, ocular involvement
did not appear to affect functional or QoL outcome measures
or overall disease severity. Similarly, oral involvement was
common, but also hadminimal effects on outcomemeasures.
Theseﬁndings suggest the need for organ-speciﬁc outcome
measures, such as the Oral Health Impact Proﬁle [25] or Ocular
Surface Disease Index [26] scales, when evaluating organ-
speciﬁc interventions. This is an important consideration in
clinical trials or interventions speciﬁcally targeted to a single
organ or disease manifestation, whereas a more sensitive and
speciﬁc scalemay be needed to pick up changes thatmight not
be captured by the NIH organ score. Despite the rarity of
gastrointestinal involvement in our cohort, it was one of themost signiﬁcant factors, associated with a high Lee Symptom
Scale score. Interestingly, although two-thirds of our pop-
ulation scored "severe" on the global scale, and NIH severity
was signiﬁcantly associated with almost every outcome
measure evaluated, patients routinely self-reported lower
severity than assessed by clinicians. This ﬁnding might reﬂect
the resiliency of this patient population with chronic illness
[17]. In fact, each patient was asked whether he or she would
choose to undergo allo-HSCT again knowing their current
outcome inadvance.Almosteverypatient responded thatheor
she would undergo allo-HSCT again evenwith foreknowledge
of how cGVHD would affect his or her life.
On univariate analysis, KPS, a known prognostic indicator
for patients with cGVHD, was associated with survival in our
cohort as well. We observed a trend toward a signiﬁcance
association between average NIH score and NIH global
severity score and survival, as was also seen in the study of
Arai et al. [21], but a longer follow-up of our cohort is needed
to establish statistical signiﬁcance. Thrombocytopenia and
progressive onset of cGVHD, which are associated with poorer
outcomes when present at the time of cGVHD diagnosis [22],
were not associated with poor outcomes in our cohort. The
discrepancy between our ﬁnding with results in the literature
likely reﬂects the fact that few of our patients were newly
diagnosed, few had features of acute GVHD, and the majority
were far out from allo-HSCT (median time from trans-
plantation, 37 months; median time from cGVHD diagnosis,
23months). In fact, as reported previously, high platelet count,
considered a nonspeciﬁc indicator of inﬂammation [16], was
associated with more severe disease in our cohort.
The most signiﬁcant association in our cohort by far was
the impact of NIH lung score on overall survival. Overall
survival at 36 months was 35% in patients with an NIH lung
score of 3, compared with 82% in those with a score <3. Lung
dysfunction has a signiﬁcant effect on NIH global severity
score, because the score is weighted for lung involvement
(lung score 1, moderate; 2 or 3, severe). The high rate of lung
dysfunction in our cohort (76% total, 34% severe) may explain
the profound impact of the NIH lung score on overall
survival. It is important to note that the NIH lung score does
not discriminate between lung GVHD and lung dysfunction
otherwise classiﬁed. Patients with lung cGVHD or bron-
chiolitis obliterans syndrome have an extremely poor prog-
nosis, lack effective therapeutic options, and have amortality
of 60%-100% in most reported series [27]. Although patients
who meet the criteria for bronchiolitis obliterans syndrome
may fall into any of the NIH lung score categories (1-3), only
those with the most severe disease (DLCO or FEV1 <39%) or
an LFS of 10-12 meet the criteria for a lung score of 3. The LFS
is computed by the extent of FEV1 and DLCO compromise
(see Supplemental Materials) [5]. This implies that stratiﬁ-
cation of lung dysfunction in the NIH score has a profound
impact on the prognostic value of pulmonary function. A
further analysis of this subset of patients with elevated NIH
lung scores is currently underway to delineate the differ-
ences between GVHD lung involvement and other lung
dysfunction in terms of impact on outcomes and survival.
Although eosinophilia was rare in our cohort (affecting
only 14 of 189 patients), it was found to be an important
independent prognostic factor for survival. Eosinophilia has
been identiﬁed as a harbinger of the development of both
acute GVHD and cGVHD [28,29]; however, previous studies
have shown an association between eosinophilia and favor-
able outcomes after allo-HSCT [30] and lower-grade cGVHD
[31-33]. However, those studies did not use NIH diagnostic
K. Baird et al. / Biol Blood Marrow Transplant 19 (2013) 632e639638criteria, and eosinophilia was evaluated at the time of cGVHD
diagnosis, in contrast to the present study, in which our
patients were far out from the time of cGVHD disgnosis. In
our cohort, eosinophilia was not correlated with speciﬁc
clinical manifestations, and the mechanism behind the
association between eosinophilia and poor survival is
unclear and merits further investigation. Although we
included intensity of immunosuppression in our model, we
did not evaluate prednisone as an independent factor, which
also may inﬂuence the impact on eosinophilia.
Potential limitations of the present study include the
severity of disease in our cohort, which might not be repre-
sentative of typical patient cohorts at other transplantation
centers. Given the nature of cross-sectional studies, and
because our cohort represented a referral population, our
cohort was enriched for refractory or persistent cGVHD
manifestations. In particular, we identiﬁed a high incidence
of lung, sclerotic skin, and joint/fascia involvement. In the
same manner, the time from allo-HSCT in our cohort
(approximately one-half of the patients were more than 3
years out from allo-HSCT) is not representative of all time
points in the cGVHD disease course, particularly the onset of
cGVHD manifestations. Despite these limitations, however,
the referral population and cross-sectional design allowed us
to acquire data from affected patients treated at dozens of
transplantation centers in the US and internationally. The
natural history study onwhich these patients were evaluated
allows for detailed evaluation with extensive, precise, and
consistent data capture. This facilitated examination of
a large population of patients with signiﬁcant disease
burden, particularly those with less common and most
disabling manifestations. The availability of parallel organ-
speciﬁc scoring by subspecialists and clinicians gave us
a unique opportunity to independently validate NIH scores
generated by transplantation clinicians.
In conclusion, the results of the present study support the
utility of the NIH cGVHD severity scores as adequate indi-
cators of disease severity in patients severely affected by
chronic GVHD, and may be an effective substitute for SSEs in
longitudinal, prospective transplantation studies. In addi-
tion, NIH lung severity score is the single most signiﬁcant
determinant of survival in this cohort.ACKNOWLEDGMENTS
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